Purpose of the analysis is to assess the cost-effectiveness and cost-utility of Giotrif® (afatinib) as first line treatment for metastatic non-small cell lung cancer NSCLC with Del 19 mutation of EGFR gene in comparison with erlotinib, gefitinib and combination cisplatin/ pemetrexed. Markov modeling was implemented to simulate clinical and economical outcomes of different strategies in treatment of na ve patients based on randomized clinical trial results. Direct medical costs were considered. Afatinib used as first line treatment in patients with NSCLC with Del 19 gene mutation increased quality-adjusted life years (QALY) by 0,354, 0,665 and 0,670 QALY in comparison with erlotinib, gefitinib and combination cisplatin/ pemetrexed respectively. The ICERs were 1 052 934, 1 067 116 и 1 064 708 rubles in comparison with erlotinib, gefitinib and combination cisplatin/ pemetrexed respectively per QALY. Afatinib was shown to be the cost-effective strategy in first line treatment of metastatic NSCLC with Del 19 gene mutation as willingness to pay threshold (1 455 741,77 rubles) was not exceeded.

Androgen deprivation remains a golden standard therapy in advance Prostate cancer. Besides adequate suppression of the tumor growth, ADT causes temporary or even permanent sexual dysfunction along with the high risk of metabolic complications. In our prospective study we have included 56 patients with advanced forms of prostrate cancer and remained sexual activity whom were subjects to different regimens of ADT. The primary goal of our study was evaluation of the degree of metabolic complications and time to regain sexual activity using continuous and intermittent GnRH analogues therapy and sequential therapy with GnRH analogues and bicalutamide.

About 70% of cases of breast cancer (BC) are hormone-dependent tumors and the main method of treatment of such patients is antiestrogen therapy. At this time, development of endocrine resistance during this type of treatment remains a significant problem. This article reviews literature on signal pathways that regulate tumor growth, mechanisms of development of endocrine resistance and possible ways to overcome it.

Over the last century, mastectomy has symbolized radical surgical treatment of breast cancer. Since the end of XIX this surgical operation has undergone significant changes due to recognize the paths of breast cancer progression. The review reveals the history of breast cancer surgery, describes and discusses the recent approaches with immediate breast reconstruction, including skinsparing and nipple-sparing modification.

Microglial cells in malignant gliomas closely interact with tumor cells. Microenvironment provides local immunosuppression, which promotes escape of tumors from immune system control. Numerous cytokines secreted by microenvironment support survival, nutrition, growth, proliferation and invasion of tumor cells. Microenvironment-targeted therapy is no less important than the traditional cytostatic therapy. Seem promising therapies aimed at reducing the recruitment of immune cells and their amounts in the tumor tissue, at neutralizationof the immunosuppressive properties of microglia and / or inversion of its suppressive phenotype, as well as disinhibition and stimulation of antineoplastic functions of microenvironment.

The substance of the skin in 100 patients with inflammatory breast cancer was studied. Diagnosed skin thickening more than 2,5–3 mm compared with a symmety part of an opposite breast. The average thickness of the skin cancer edema is 5,6 mm and maximum one is 14 mm. The sensitivity of the digital mammography and sonography was 97%, of plikometry – 94%. Digitally instrumental determination of skin thickness using radiodiagnostic methods and by plikometry is precise and objective method of diagnostic of breast cancer edema.

Breast-conserving therapy is well-controlled, safe and efficacious treatment for early-stage breast cancer. Breast-conserving therapy is culmination of fight for the nature breast after breast cancer. The use of the BCT for early-stage breast cancer is widely accepted and is mow the treatment of choice in the many countries. Well known that localisation of the tumour in the upperinner quadrant of the breast is difficult for the optimal result after BCT due to insufficient tissue in the upper pole. In our practice we use the new kind of BCT with the flap under the name («no name flap»). This technique has been demonstrated excellent cosmetic and oncological results.